Arrowhead Pharmaceuticals (ARWR) Competitors $29.42 +0.75 (+2.62%) Closing price 04:00 PM EasternExtended Trading$28.82 -0.60 (-2.04%) As of 05:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ARWR vs. SMMT, ASND, VTRS, RDY, QGEN, BBIO, MRNA, ELAN, VRNA, and ROIVShould you be buying Arrowhead Pharmaceuticals stock or one of its competitors? The main competitors of Arrowhead Pharmaceuticals include Summit Therapeutics (SMMT), Ascendis Pharma A/S (ASND), Viatris (VTRS), Dr. Reddy's Laboratories (RDY), Qiagen (QGEN), BridgeBio Pharma (BBIO), Moderna (MRNA), Elanco Animal Health (ELAN), Verona Pharma PLC American Depositary Share (VRNA), and Roivant Sciences (ROIV). These companies are all part of the "pharmaceutical products" industry. Arrowhead Pharmaceuticals vs. Its Competitors Summit Therapeutics Ascendis Pharma A/S Viatris Dr. Reddy's Laboratories Qiagen BridgeBio Pharma Moderna Elanco Animal Health Verona Pharma PLC American Depositary Share Roivant Sciences Summit Therapeutics (NASDAQ:SMMT) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, institutional ownership, earnings, media sentiment, profitability and risk. Is SMMT or ARWR more profitable? Arrowhead Pharmaceuticals' return on equity of -40.91% beat Summit Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Summit TherapeuticsN/A -208.64% -181.28% Arrowhead Pharmaceuticals N/A -40.91%-11.62% Does the media prefer SMMT or ARWR? In the previous week, Summit Therapeutics had 8 more articles in the media than Arrowhead Pharmaceuticals. MarketBeat recorded 24 mentions for Summit Therapeutics and 16 mentions for Arrowhead Pharmaceuticals. Summit Therapeutics' average media sentiment score of 1.03 beat Arrowhead Pharmaceuticals' score of 0.55 indicating that Summit Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Summit Therapeutics 7 Very Positive mention(s) 6 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Arrowhead Pharmaceuticals 4 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable earnings and valuation, SMMT or ARWR? Summit Therapeutics has higher earnings, but lower revenue than Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Summit Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSummit Therapeutics$700K19,229.20-$221.32M-$1.01-17.94Arrowhead Pharmaceuticals$3.55M1,145.81-$599.49M-$1.28-22.98 Do institutionals & insiders believe in SMMT or ARWR? 4.6% of Summit Therapeutics shares are held by institutional investors. Comparatively, 62.6% of Arrowhead Pharmaceuticals shares are held by institutional investors. 84.9% of Summit Therapeutics shares are held by insiders. Comparatively, 4.3% of Arrowhead Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Do analysts recommend SMMT or ARWR? Summit Therapeutics presently has a consensus target price of $33.79, indicating a potential upside of 86.46%. Arrowhead Pharmaceuticals has a consensus target price of $43.14, indicating a potential upside of 46.64%. Given Summit Therapeutics' higher probable upside, equities research analysts clearly believe Summit Therapeutics is more favorable than Arrowhead Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Summit Therapeutics 3 Sell rating(s) 1 Hold rating(s) 12 Buy rating(s) 1 Strong Buy rating(s) 2.65Arrowhead Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 2 Strong Buy rating(s) 3.00 Which has more volatility and risk, SMMT or ARWR? Summit Therapeutics has a beta of -1.02, indicating that its stock price is 202% less volatile than the S&P 500. Comparatively, Arrowhead Pharmaceuticals has a beta of 1, indicating that its stock price has a similar volatility profile to the S&P 500. SummarySummit Therapeutics beats Arrowhead Pharmaceuticals on 9 of the 16 factors compared between the two stocks. Get Arrowhead Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ARWR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ARWR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARWR vs. The Competition Export to ExcelMetricArrowhead PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.07B$3.09B$5.70B$10.27BDividend YieldN/A2.32%5.72%4.60%P/E Ratio-22.9821.3075.8626.51Price / Sales1,145.81380.87491.12165.50Price / CashN/A44.4425.8129.89Price / Book19.109.6112.846.32Net Income-$599.49M-$53.28M$3.28B$270.51M7 Day Performance6.09%0.32%0.22%2.15%1 Month Performance43.44%4.59%4.61%6.35%1 Year Performance43.86%9.24%68.33%25.49% Arrowhead Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARWRArrowhead Pharmaceuticals4.1377 of 5 stars$29.42+2.6%$43.14+46.6%+33.4%$4.07B$3.55M-22.98400SMMTSummit Therapeutics3.3658 of 5 stars$19.44-25.2%$33.79+73.8%-40.7%$14.44B$700K-19.25110Positive NewsAnalyst ForecastHigh Trading VolumeASNDAscendis Pharma A/S3.0157 of 5 stars$205.22-0.3%$244.36+19.1%+63.2%$12.56B$393.54M-39.771,017Positive NewsVTRSViatris1.5918 of 5 stars$10.48-0.2%$10.40-0.8%-17.7%$12.22B$14.74B-3.6132,000RDYDr. Reddy's Laboratories2.426 of 5 stars$14.27-0.5%$16.95+18.8%-9.0%$11.91B$334.26B21.6127,811Positive NewsQGENQiagen4.4194 of 5 stars$47.62+0.1%$49.69+4.4%+0.7%$10.58B$1.98B28.135,765BBIOBridgeBio Pharma4.4324 of 5 stars$54.29+1.7%$63.35+16.7%+96.6%$10.38B$221.90M-13.27400Analyst ForecastMRNAModerna4.4442 of 5 stars$24.83-1.2%$42.88+72.7%-65.0%$9.66B$3.24B-3.305,800ELANElanco Animal Health2.8161 of 5 stars$19.02+3.2%$17.33-8.9%+28.7%$9.45B$4.44B22.129,000Positive NewsVRNAVerona Pharma PLC American Depositary Share2.2977 of 5 stars$106.300.0%$109.00+2.5%+257.2%$9.19B$42.28M-107.3730Positive NewsROIVRoivant Sciences2.9366 of 5 stars$12.91-0.1%$16.38+26.8%+16.8%$8.82B$29.05M-18.44860 Related Companies and Tools Related Companies Summit Therapeutics Alternatives Ascendis Pharma A/S Alternatives Viatris Alternatives Dr. Reddy's Laboratories Alternatives Qiagen Alternatives BridgeBio Pharma Alternatives Moderna Alternatives Elanco Animal Health Alternatives Verona Pharma PLC American Depositary Share Alternatives Roivant Sciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ARWR) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersFanatics Hit $31B-Is This Nasdaq Next?Fanatics built an empire by owning the fan experience-scaling to a $31B valuation. But the next wave isn't abo...i2i Marketing Group, LLC | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredOpenAI’s new $300 billion dealOpenAI just signed a $300 billion cloud deal with Oracle to secure the computing power needed for its next Cha...Porter & Company | SponsoredNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arrowhead Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arrowhead Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ARWR Stock Alerts